Mher Onanyan, MD
Pulmonary Disease · Mission Hills, CANPI 1861755241
Payments from drug & device makers
What this record shows
This record is dominated by education: $6,015 of the $8,265 with a category attached, or 72.8%. Intuitive Surgical accounts for 78.9% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $6,549 and has fallen 96.2% since, to $250 in 2025.
Across 62 payments — averaging $133.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Boehringer Ingelheim$498
- AstraZeneca$222
- Johnson & Johnson$200
- Inari Medical, Inc.$166
- GSK$122
- plus $537 from 15 others
What the payments were for
- Travel & lodging$3064%
- Food & beverage$1,94424%
- Education$6,01573%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $6,520 |
| Boehringer Ingelheim | 5 | $498 |
| AstraZeneca | 4 | $222 |
| Johnson & Johnson | 4 | $200 |
| Inari Medical, Inc. | 1 | $166 |
| GSK | 7 | $122 |
| Electromed, Inc. | 10 | $111 |
| Novo Nordisk | 5 | $91 |
| Merck | 3 | $59 |
| Sunovion Pharmaceuticals Inc. | 3 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $33 |
| Astellas Pharma US Inc | 2 | $28 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Bayer | 1 | $22 |
| ERBE USA Inc | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| CSL Behring | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Amgen | 1 | $14 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,382
- ION$3,000
- OFEV$251
- FLOWTRIEVER CATHETER, S$166
- CT THROMBECTOMY SYSTEM KIT$166
- FARXIGA$125
How this compares
$8,265 in reported general payments places this provider in the 75th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 243 | $173,931 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 175 | $96,600 |
| Breo ElliptaFluticasone/Vilanterol | 126 | $59,855 |
| Spiriva RespimatTiotropium Bromide | 72 | $39,201 |
| Spiriva HandihalerTiotropium Bromide | 45 | $27,747 |
| Wixela InhubFluticasone Propion/Salmeterol | 123 | $12,475 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 479 | $10,915 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 118 | $10,804 |
| Atrovent HfaIpratropium Bromide | 19 | $8,676 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $6,299 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $5,368 |
| BreynaBudesonide/Formoterol Fumarate | 22 | $2,497 |
| Fluconazole | 16 | $1,293 |
| Proair RespiclickAlbuterol Sulfate | 18 | $1,267 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 18 | $985 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $122 | $336,685558 claims |
| Boehringer IngelheimSpiriva Respimat | $498 | $39,20172 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Mission Hills
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.